共 143 条
[1]
Kanis JA(2000)An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation Osteoporos Int 11 192-202
[2]
Gluer CC(2013)Osteoporosis in the European Union: medical management, epidemiology and economic burden Arch Osteoporos 8 1-115
[3]
Hernlund E(2003)Cost effectiveness of alendronate (fosamax(registered trademark)) for the treatment of osteoporosis and prevention of fractures Pharmacoeconomics 21 305-314
[4]
Svedbom A(2008)Cost-effective osteoporosis treatment thresholds: the United States perspective Osteoporos Int 19 437-447
[5]
Ivergård M(2010)The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX Osteoporos Int 21 495-505
[6]
Compston J(2014)A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures Osteoporos Int 25 51-60
[7]
Cooper C(2001)Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions Osteoporos Int 12 849-857
[8]
Stenmark J(1999)Health-related quality of life in economic evaluations for osteoporosis: whose values should we use? Med Decis Mak 19 141-148
[9]
McCloskey EV(1997)The quality of well-being scale: comparison of the interviewer-administered version with a self-administered questionnaire Psychol Health 12 783-791
[10]
Jönsson B(1995)Multi-attribute health status classification systems. Health Utilities Index Pharmacoeconomics 7 490-502